A Multicentre, Randomised, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of HSK7653 as Monotherapy in Chinese Patients With Type 2 Diabetes
Latest Information Update: 03 Aug 2023
At a glance
- Drugs Cofrogliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Sichuan Haisco Pharmaceutical
- 26 Jun 2023 Primary endpoint (HbA1c change from baseline at week 24) has been met according to Results presented at the 83rd Annual Scientific Sessions of the American Diabetes Association
- 26 Jun 2023 Results assessing the efficacy and safety of HSK7653 biweekly as monotherapy for 52 weeks in drug naive type 2 diabetes patients with inadequate glycemic control on diet and exercise presented at the 83rd Annual Scientific Sessions of the American Diabetes Association
- 09 Dec 2022 Status changed from recruiting to completed.